Vitamin D receptor activators.
The fields for clinical employment of vitamin D analogs are growing and under active evaluation in different medical specialties, ranging from dermatology to immunology and oncology. In this review we provide a brief description of the drugs that have been developed more specifically for the treatment of secondary hyperparathyroidism (SH) associated with uremia.
Mazzaferro
Sandro
S
Department of Clinical Science, Sapienza University of Rome and Chair of Nephrology, Sapienza University of Rome, Rome - Italy. sandro.mazzaferro@unirmoma1.it
Pasquali
Marzia
M
Conte
Carmina
C
Mandanici
Giusy
G
Muci
Maria
M
Lavini
Raffaella
R
D002117:Calcitriol / Q000031:analogs & derivatives / Q000627:therapeutic use; D004100:Dihydroxycholecalciferols / Q000627:therapeutic use; D004872:Ergocalciferols / Q000627:therapeutic use; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology; D014511:Uremia / Q000150:complications; D014807:Vitamin D / Q000031:analogs & derivatives*; D005466:Fluorocarbons
D002117:Calcitriol; D004100:Dihydroxycholecalciferols; D004872:Ergocalciferols; D014807:Vitamin D; C042533:1 alpha-hydroxyergocalciferol; C084656:paricalcitol; C040488:26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3; D005466:Fluorocarbons; C521167:2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol